Cited by 1,009Metabolism, Diabetes, and CancerCancer Risks and FactorsGrowth Hormone and Insulin-like Growth Factors

The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.

Diabetes and cancer

Open access

Vigneri, Paolo, Frasca, Francesco, Sciacca, Laura, Pandini, Giuseppe, Vigneri, Riccardo·2009·Endocrine Related Cancer

Open this paper in CoChat — free account Open PDF

Abstract

Diabetes and cancer are two heterogeneous, multifactorial, severe, and chronic diseases. Because of their frequency, reciprocal influences - even minor influences - may have a major impact. Epidemiological studies clearly indicate that the risk of several types of cancer (including pancreas, liver, breast, colorectal, urinary tract, and female reproductive organs) is increased in diabetic patients. Mortality is also moderately increased. Several confounding factors, having general or site-specific relevance, make it difficult to accurately assess cancer risk in diabetic patients. These factors include diabetes duration, varying levels of metabolic control, different drugs used for therapy, and the possible presence of chronic complications. Hyperinsulinemia most likely favors cancer in diabetic patients as insulin is a growth factor with pre-eminent metabolic but also mitogenic effects, and its action in malignant cells is favored by mechanisms acting at both the receptor and post-receptor level. Obesity, hyperglycemia, and increased oxidative stress may also contribute to increased cancer risk in diabetes. While anti-diabetic drugs have a minor influence on cancer risk (except perhaps the biguanide metformin that apparently reduces the risk), drugs used to treat cancer may either cause diabetes or worsen a pre-existing diabetes. In addition to the well-known diabetogenic effect of glucocorticoids and anti-androgens, an increasing number of targeted anti-cancer molecules may interfere with glucose metabolism acting at different levels on the signaling substrates shared by IGF-I and insulin receptors. In conclusion, diabetes and cancer have a complex relationship that requires more clinical attention and better-designed studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1677/erc-09-0087

Cites

187 of 187 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

On the origin of cancer cells
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
Hoskins, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(1911) · JAMA · doi:10.1001/jama.1911.04260070032017 · Cited by 3,355
Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988–1994
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Diabetes and Cancer
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The American Journal of Gastroenterology
(2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.80003397.x · Cited by 2,202
Insulin and insulin-like growth factor signalling in neoplasia
Pollak, M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2536 · Cited by 2,059
Archives of Biochemistry and Biophysics
Carter, H. E., Bhattacharyya, P., Weidman, K. R., & Fraenkel, G. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1981.tb06727.x · Cited by 1,895
Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance
Kern, P. A., Ranganathan, S., Li, C., Wood, L., & Ranganathan, G. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.280.5.e745 · Cited by 1,883
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
Renehan, A. G., Zwahlen, M., Minder, C., O'Dwyer, S. T., Shalet, S. M., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16044-3 · Cited by 1,697
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H. M., Giles, F. J., Wunderle, L., Bhalla, K. N., O'Brien, S. M., Waßmann, B., Tanaka, C., Manley, P. W., Rae, P., Mietlowski, W. L., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,334
The tor pathway: a target for cancer therapy
Bjornsti, M., & Houghton, P. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1362 · Cited by 1,318
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients
Eisen, H. J., Tuzcu, E. M., Dorent, R., KOBASHIGAWA, J. A., MANCINI, D. M., Valantine, H. A., Starling, R. C., Sørensen, K. E., Hummel, M. W., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,194
AMP-activated protein kinase signaling in metabolic regulation
Long, Y. C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29044 · Cited by 1,125
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
The insulin-like growth factor system and cancer
LeRoith, D., & Roberts, C. T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00159-9 · Cited by 1,124
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
Huxley, R., Ansary-Moghaddam, A., Berrington de González, A., Barzi, F., & Woodward, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602619 · Cited by 1,105
Proceedings of the Society for Experimental Biology and Medicine
(2010) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1111/(issn)1525-1373 · Cited by 1,098
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women
Endogenous Hormones Breast Cancer Collaborative Group (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg022 · Cited by 1,093
Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,058
Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-Analysis
Larsson, S. C., Orsini, N., & Wolk, A. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji375 · Cited by 1,038
Chronic inflammation and oxidative stress in human carcinogenesis
Federico, A., Morgillo, F., Tuccillo, C., Ciardiello, F., & Loguercio, C. (2007) · International Journal of Cancer · doi:10.1002/ijc.23192 · Cited by 1,001
Breast Cancer Research and Treatment
Alexander, M. C. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006151427889 · Cited by 994
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., Golub, T. R., et al. (2004) · Nature Medicine · doi:10.1038/nm1052 · Cited by 964
Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells
Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., & Vigneri, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3278 · Cited by 897
Diabetes mellitus and risk of breast cancer: A meta‐analysis
Larsson, S. C., Mantzoros, C. S., & Wolk, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22717 · Cited by 884
Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus: A Systematic Review and Meta-analysis
Barone, B. B. (2008) · JAMA · doi:10.1001/jama.2008.824 · Cited by 881
The Israel Medical Association journal
(2022) · The Israel Medical Association journal : IMAJ · doi:10.54853/15651088 · Cited by 878
The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic Evidence
El‐Serag, H. B., Hampel, H., & Javadi, F. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.007 · Cited by 831
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 809
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. M., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis
Everhart, J. (1995) · JAMA · doi:10.1001/jama.273.20.1605 · Cited by 747
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study
Davila, J., Morgan, R., Shaib, Y., McGlynn, K., & El-Serag, H. (2005) · Gut · doi:10.1136/gut.2004.052167 · Cited by 707
Obesity, Hypertension, and the Risk of Kidney Cancer in Men
Chow, W., Gridley, G., Fraumeni, J. F., & Järvholm, B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431804 · Cited by 667
Chemical basis of inflammation-induced carcinogenesis
Ohshima, H., Tatemichi, M., & Sawa, T. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(03)00283-2 · Cited by 623
Prevalence and Clinical Profile of Pancreatic Cancer–Associated Diabetes Mellitus
Pannala, R., Leirness, J. B., Bamlet, W. R., Basu, A., Petersen, G. M., & Chari, S. T. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.039 · Cited by 621
Maintenance Immunosuppression with Target-of-Rapamycin Inhibitors is Associated with a Reduced Incidence of De Novo Malignancies
Kauffman, H. M., Cherikh, W. S., Cheng, Y., Hanto, D. W., & Kahan, B. D. (2005) · Transplantation · doi:10.1097/01.tp.0000184006.43152.8d · Cited by 619
Energy balance and cancer: the role of insulin and insulin-like growth factor-I
Kaaks, R., & Lukanova, A. (2001) · Proceedings of The Nutrition Society · doi:10.1079/pns200070 · Cited by 610
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607
Probability of Pancreatic Cancer Following Diabetes: A Population-Based Study
Chari, S. T., Leibson, C. L., Rabe, K. G., Ransom, J., de Andrade, M., & Petersen, G. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.007 · Cited by 603
Leptin and cancer
Garofalo, C., & Surmacz, E. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20472 · Cited by 597
Diabetes mellitus and risk of endometrial cancer: a meta-analysis
Friberg, E., Orsini, N., Mantzoros, C. S., & Wolk, A. (2007) · Diabetologia · doi:10.1007/s00125-007-0681-5 · Cited by 577
New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer
Pannala, R., Basu, A., Petersen, G. M., & Chari, S. T. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70337-1 · Cited by 577
Insulin-like growth factors and cancer
Fürstenberger, G., & Senn, H.-J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00731-3 · Cited by 538
Obesity and Breast Cancer: The Estrogen Connection
Cleary, M. P., & Grossmann, M. E. (2009) · Endocrinology · doi:10.1210/en.2009-0070 · Cited by 525
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro
Alimova, I. N., Liu, B., Fan, Z., Edgerton, S. M., Dillon, T., Lind, S. E., & Thor, A. D. (2009) · Cell Cycle · doi:10.4161/cc.8.6.7933 · Cited by 523
Third national health and nutrition examination survey
Maurer, K. R. (1985) · American Heart Journal · doi:10.1016/0002-8703(85)90062-6 · Cited by 523
Pancreatic Cancer–Associated Diabetes Mellitus: Prevalence and Temporal Association With Diagnosis of Cancer
Chari, S. T., Leibson, C. L., Rabe, K. G., Timmons, L. J., Ransom, J. E., de Andrade, M., & Petersen, G. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.10.040 · Cited by 519
Clinical Gastroenterology and Hepatology
Ghosh, S. (2006) · Gut · doi:10.1136/gut.2006.097675 · Cited by 512
Glucocorticoid-induced hyperglycemia
Clore, J. N., & Thurby-Hay, L. (2009) · Endocrine Practice · doi:10.4158/ep08331.rar · Cited by 508
A meta-analysis of diabetes mellitus and the risk of prostate cancer
Kasper, J. S., & Giovannucci, E. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0410 · Cited by 491
Greater Survival After Breast Cancer in Physically Active Women With High Vegetable-Fruit Intake Regardless of Obesity
Pierce, J. P., Stefanick, M. L., Flatt, S. W., Natarajan, L., Sternfeld, B., Madlensky, L., Al‐Delaimy, W. K., Thomson, C. A., Kealey, S., Hajek, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6819 · Cited by 463
Physiological and molecular mechanisms involved in nutritional regulation of fatty acid synthesis
Hillgartner, F. B., Salati, L. M., & Goodridge, A. G. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.1.47 · Cited by 459
Leptin--A Growth Factor in Normal and Malignant Breast Cells and for Normal Mammary Gland Development
Hu, X. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.22.1704 · Cited by 457
AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome
Ruderman, N., & Prentki, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1344 · Cited by 451
Breast Cancer Incidence, 1980 2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status
Glass, A. G., Lacey, J. V., Carreon, J. D., & Hoover, R. N. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm059 · Cited by 439
AMPK, the metabolic syndrome and cancer
Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.011 · Cited by 426
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis
Ma, J., Li, H., Giovannucci, E., Mucci, L., Qiu, W., Nguyen, P. L., Gaziano, J. M., Pollak, M., & Stampfer, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70235-3 · Cited by 421
Abnormal Glucose Metabolism and Pancreatic Cancer Mortality
Gapstur, S. M. (2000) · JAMA · doi:10.1001/jama.283.19.2552 · Cited by 420
The role of insulin receptors and IGF-I receptors in cancer and other diseases
Frasca, F., Pandini, G., Sciacca, L., PEZZINO, V., Squatrito, S., Belfiore, A., & Vigneri, R. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801969715 · Cited by 414
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden
Jonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
SDRN Epidemiology Group, & Colhoun, H. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1453-1 · Cited by 387
Impact of Diabetes Mellitus on Outcomes in Patients With Colon Cancer
Meyerhardt, J. A., Catalano, P. J., Haller, D. G., Mayer, R. J., Macdonald, J. S., Benson, A. B., & Fuchs, C. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.125 · Cited by 378
Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes
Fernández, A. M., Kim, J. K., Yakar, S., Dupont, J., Hernandez-Sanchez, C., Castle, A. L., Filmore, J., Shulman, G. I., & Le Roith, D. (2001) · Genes & Development · doi:10.1101/gad.908001 · Cited by 369
Tumour necrosis factor-α as a tumour promoter
Szlosarek, P. W., Charles, K. A., & Balkwill, F. R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.012 · Cited by 367
Fasting glucose is a risk factor for breast cancer: a prospective study.
Muti, P. C., Quattrin, T., Grant, B. J. B., Krogh, V., Micheli, A., Schünemann, H. J., Ram, M., Freudenheim, J. L., Sieri, S., Trevisan, M., et al. (2002) · PubMed · Cited by 358
Nutrition, hormones, and breast cancer: Is insulin the missing link?
Kaaks, R. (1996) · Cancer Causes & Control · doi:10.1007/bf00051703 · Cited by 354
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.01.047 · Cited by 349
Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1
LeRoith, D., & Yakar, S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0427 · Cited by 344
Elevated insulin receptor content in human breast cancer
Papa, V, Pezzino, V, Costantino, A., Belfiore, A., Giuffrida, D., Frittitta, L., Vannelli, G. B., Brand, R., Goldfine, I. D., & Vigneri, R. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114868 · Cited by 338
Self-citation
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
Diabetes mellitus and risk of prostate cancer: a meta-analysis
Bonovas, S., Filioussi, K., & Tsantes, A. (2004) · Diabetologia · doi:10.1007/s00125-004-1415-6 · Cited by 332
Tissue-Specific Expression of Two Alternatively Spliced Insulin Receptor mRNAs in Man
Moller, D. E., Yokota, A., Caro, J. F., & Flier, J. S. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-8-1263 · Cited by 326
Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling
Ihle, N. T., Williams, R. R., Chow, S., Chew, W. M., Berggren, M. I., Paine-Murrieta, G. D., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R. T., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 317
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
Hassan, M. M., Curley, S. A., Li, D., Kaseb, A. O., Davila, M. L., Abdalla, E. K., Javle, M. M., Moghazy, D. M., Lozano, R. D., Abbruzzese, J. L., et al. (2010) · Cancer · doi:10.1002/cncr.24982 · Cited by 308
The role of the lipogenic pathway in the development of hepatic steatosis
Postic, C., & Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74599-3 · Cited by 307
Diabetes mellitus and risk of bladder cancer: a meta-analysis
Larsson, S. C., Orsini, N., Brismar, K., & Wolk, A. (2006) · Diabetologia · doi:10.1007/s00125-006-0468-0 · Cited by 304
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Rhodes, N., Heerding, D. A., Duckett, D. R., Eberwein, D. J., Knick, V. B., Lansing, T. J., McConnell, R. T., Gilmer, T. M., Zhang, S., Robell, K. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5783 · Cited by 299
Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism
Sciacca, L., Costantino, A., Pandini, G., Mineo, R., Frasca, F., Scalia, P., Sbraccia, P., Goldfine, I. D., Vigneri, R., & Belfiore, A. (1999) · Oncogene · doi:10.1038/sj.onc.1202600 · Cited by 289
Lower Endogenous Androgen Levels and Dyslipidemia in Men with Non-Insulin-Dependent Diabetes Mellitus
Barrett-Connor, E. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-10-807 · Cited by 281
Cancer Incidence in Patients With Type 1 Diabetes Mellitus: A Population-Based Cohort Study in Sweden
Zendehdel, K. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg105 · Cited by 280
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D. R., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 275
Colorectal Cancer: Another Complication of Diabetes Mellitus?
Will, J. C., Galuska, D. A., Vinicor, F., & Calle, E. E. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009534 · Cited by 274
Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors
Haluska, P., Shaw, H. M., Batzel, G. N., Yin, D., Molina, J. R., Molife, L. R., Yap, T. A., Roberts, M. L., Sharma, A., Gualberto, A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1118 · Cited by 269
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1–deficient mice
Yakar, S., Setser, J., Zhao, H., STANNARD, B. S., Haluzı́k, M., Glatt, V., Bouxsein, M., Kopchick, J. J., & LeRoith, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci17763 · Cited by 249
The Insulin-Pancreatic Acinar Axis
Williams, J. A., & Goldfine, I. D. (1985) · Diabetes · doi:10.2337/diab.34.10.980 · Cited by 248
High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes
Buzzetti, R., Di Pietro, S., Giaccari, A., Petrone, A., Locatelli, M., Suraci, C., Capizzi, M., Arpi, M. L., Bazzigaluppi, E., Dotta, F., et al. (2007) · Diabetes Care · doi:10.2337/dc06-1696 · Cited by 242
A Novel Autocrine Loop Involving IGF-II and the Insulin Receptor Isoform-A Stimulates Growth of Thyroid Cancer
Vella, V., Pandini, G., Sciacca, L., Mineo, R., Vigneri, R., PEZZINO, V., & Belfiore, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.1.8142 · Cited by 240
Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs
Markussen, J., Havelund, S., Kurtzhals, P., Andersen, A. S., Halstr�m, J., Hasselager, E., Larsen, U. D., Ribel, U., Sch�ffer, L., Vad, K., et al. (1996) · Diabetologia · doi:10.1007/bf00418343 · Cited by 233
Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study
Lorber, M. I., Mulgaonkar, S. P., Butt, K. M. H., ELKHAMMAS, E. A., Mendez, R., Rajagopalan, P. R., Kahan, B. D., Sollinger, H. W., Li, Y., Cretin, N., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000164352.65613.24 · Cited by 231
The Insulin Receptor and Its Cellular Targets1
Kido, Y., Nakae, J., & Accili, D. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7306 · Cited by 228
The role of diabetes mellitus in the aetiology of renal cell cancer
Lindblad, P., Chow, W. H., Chan, J., Bergström, A., Wolk, A., Gridley, G., McLaughlin, J. K., Nyrén, O., & Adami, H. O. (1999) · Diabetologia · doi:10.1007/s001250051122 · Cited by 220
Relationship between carbohydrate-induced hypertriglyceridemia and fatty acid synthesis in lean and obese subjects
Hudgins, L. C., Hellerstein, M. K., Seidman, C. E., Neese, R. A., Tremaroli, J. D., & Hirsch, J. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32407-x · Cited by 216
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
Panwalkar, A. W., Verstovšek, S., & Giles, F. J. (2004) · Cancer · doi:10.1002/cncr.20026 · Cited by 206
Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis
Stevens, R., Roddam, A. W., & Beral, V. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603571 · Cited by 201
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1–deficient mice
Yakar, S., Setser, J., Zhao, H., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200417763 · Cited by 201
Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?
Lupu, R., & Menéndez, J. A. (2006) · Current Pharmaceutical Biotechnology · doi:10.2174/138920106779116928 · Cited by 196
Fatty Acid Synthase: Association with Insulin Resistance, Type 2 Diabetes, and Cancer
Menéndez, J. A., Vázquez‐Martín, A., Ortega, F. J., & Fernández‐Real, J. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.115352 · Cited by 182
In vitro and In vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417
Haluska, P., Carboni, J. M., Loegering, D. A., Lee, F. Y., Wittman, M. D., Saulnier, M. G., Frennesson, D. B., Kalli, K. R., Conover, C. A., Attar, R. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1107 · Cited by 180
Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells
Weinstein, D., Simon, M., Yehezkel, E., Laron, Z., & Werner, H. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.912 · Cited by 179
The IGF system in thyroid cancer: new concepts
Vella, V., Sciacca, L., Pandini, G., Mineo, R., Squatrito, S., Vigneri, R., & Belfiore, A. (2001) · Molecular Pathology · doi:10.1136/mp.54.3.121 · Cited by 177
The impact of diabetes on survival following breast cancer
Lipscombe, L. L., Goodwin, P. J., Zinman, B., McLaughlin, J. R., & Hux, J. E. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9654-0 · Cited by 176
Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia
DeRemer, D. L., Ustun, C., & Natarajan, K. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.11.014 · Cited by 172
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
Joaquim Bellmunt, B., Szczylik, C. A., Feingold, J. M., Strahs, A. L., & Berkenblit, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn066 · Cited by 170
Enhanced Mitogenic Signaling in Skeletal Muscle of Women With Polycystic Ovary Syndrome
Corbould, A. M., Zhao, H., Mirzoeva, S., Aird, F., & Dunaif, A. E. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-0453 · Cited by 166
Growth Hormone Regulation of p85α Expression and Phosphoinositide 3-Kinase Activity in Adipose Tissue
del Rincon, J. P., Iida, K., Gaylinn, B. D., McCurdy, C. E., Leitner, J. W., Barbour, L. A., Kopchick, J. J., Friedman, J. E., Draznin, B., & Thorner, M. O. (2007) · Diabetes · doi:10.2337/db06-0299 · Cited by 164
Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma
Lacy, M. Q., Alsina, M., Fonseca, R., Paccagnella, M. L., Melvin, C. L., Yin, D., Sharma, A., Enriquez-Sarano, M. L., Pollak, M., Jagannath, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9319 · Cited by 164
Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry
Yang, X., Ko, G. T. C., So, W. Y., Ronald, C. W., Yu, L. W. L., Kong, A. P. S., Zhao, H., Chow, C., Tong, P. C. Y., & Chan, J. C. N. (2010) · Diabetes · doi:10.2337/db09-1371 · Cited by 162
Trial of Insulinlike Growth Factor I Therapy for Patients With Extreme Insulin Resistance Syndromes
Kuzuya, H., Matsuura∥, N., Sakamoto, M., Makino, H., Sakamoto, Y., Kadowaki, T., Suzuki, Y., Kobayashi, M., Akazawa, Y., Nomura, M., et al. (1993) · Diabetes · doi:10.2337/diab.42.5.696 · Cited by 157
Functional Insulin Receptors on Human Epithelial Ovarian Carcinoma Cells: Implications for IGF-II Mitogenic Signaling
Kalli, K. R., Falowo, O. I., Bale, L. K., Zschunke, M. A., Roche, P. C., & Conover, C. A. (2002) · Endocrinology · doi:10.1210/en.2001-211408 · Cited by 154
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo
Ji, Q., Mulvihill, M. J., Rosenfeld-Franklin, M., Cooke, A. R., Feng, L., Mak, G., O’Connor, M., Yao, Y., Pirritt, C., Buck, E. A., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0070 · Cited by 152
Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction.
Heuson, J.-C., & Legros, N. (1972) · PubMed · Cited by 151
In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites
Sommerfeld, M. R., Müller, G. A., Tschank, G., Seipke, G., Habermann, P., Kurrle, R., & Tennagels, N. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009540 · Cited by 150
Insulin glargine and malignancy: an unwarranted alarm
Pocock, S., & Smeeth, L. L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61307-6 · Cited by 149
Hypertension, obesity and their medications in relation to renal cell carcinoma
Yuan, J.-M., Castelao, J. E., Gago-Domínguez, M., Ross, R. K., & Yu, M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.248 · Cited by 148
Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling
Sciacca, L., Cassarino, M. F., Genua, M., Pandini, G., Moli, R. L., Squatrito, S., & Vigneri, R. (2010) · Diabetologia · doi:10.1007/s00125-010-1760-6 · Cited by 142
Diabetes and Risk of Non-Hodgkin's Lymphoma
Mitri, J., Castillo, J. J., & Pittas, A. G. (2008) · Diabetes Care · doi:10.2337/dc08-1034 · Cited by 140
Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer
Saylor, P. J., & Smith, M. R. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.11.017 · Cited by 138
Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer
Hofmann, F., & Garcı́a-Echeverrı́a, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03512-9 · Cited by 136
Is it Time to Test Metformin in Breast Cancer Clinical Trials?
Cazzaniga, M., Bonanni, B., Guerrieri‐Gonzaga, A., & DeCensi, A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0871 · Cited by 134
Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
Crouthamel, M., Kahana, J. A., Korenchuk, S., Zhang, S., Sundaresan, G., Eberwein, D. J., Brown, K. K., & Kumar, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1253 · Cited by 134
Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines
Shukla, A., Grisouard, J., Ehemann, V., Hermani, A., Enzmann, H., & Mayer, D. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0240 · Cited by 130
Imatinib and Regression of Type 2 Diabetes
Veneri, D., Franchini, M., & Bonora, E. (2005) · New England Journal of Medicine · doi:10.1056/nejm200503103521023 · Cited by 129
High seroprevalence ofHelicobacter pylori in diabetes mellitus patients
Oldenburg, B. F., Diepersloot, R. J. A., & Hoekstra, J. B. L. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02282318 · Cited by 126
Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer
Stadler, J., Yeung, K. S., Furrer, R., Marcon, N. E., Himal, H. S., & Bruce, W. R. (1988) · Cancer Letters · doi:10.1016/0304-3835(88)90023-7 · Cited by 126
Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats.
Heuson, J.-C., Legros, N., & Heimann, R. (1972) · PubMed · Cited by 120
Clinically Confirmed Type 2 Diabetes Mellitus and Colorectal Cancer Risk: A Population-Based, Retrospective Cohort Study
Limburg, P. J., Vierkant, R. A., Fredericksen, Z. S., Leibson, C. L., Rizza, R. A., Gupta, A., Ahlquist, D. A., Melton, L. J., Sellers, T. A., & Cerhan, J. R. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00725.x · Cited by 118
Targeting Fatty Acid Synthase in Breast and Endometrial Cancer: An Alternative to Selective Estrogen Receptor Modulators?
Lupu, R., & Menéndez, J. A. (2006) · Endocrinology · doi:10.1210/en.2006-0486 · Cited by 117
The kinetics of insulin in man. II. Role of the liver
Ferrannini, E., & Cobelli, C. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030202 · Cited by 114
Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
Mannucci, E., Monami, M., Balzi, D., Cresci, B., Pala, L., Melani, C., Lamanna, C., Bracali, I., Bigiarini, M., Barchielli, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-0476 · Cited by 114
Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase
Zeng, L., Biernacka, K. M., Holly, J. M. P., Jarrett, C., Morrison, A. A., Morgan, A., Winters, Z., Foulstone, E. J., Hamilton-Shield, J. P., & Perks, C. M. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0221 · Cited by 113
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality
Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., & Mannucci, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.736 · Cited by 111
No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis
Dejgaard, A., Lynggaard, H., Råstam, J., & Thomsen, M. (2009) · Diabetologia · doi:10.1007/s00125-009-1568-4 · Cited by 109
Cancer risks in thiazolidinedione users compared to other anti-diabetic agents
Koro, C., Barrett, S., & Qizilbash, N. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1352 · Cited by 107
Peroxisomal Proliferator-Activated Receptor-γ Agonists Induce Partial Reversion of Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer Cells
Aiello, A., Pandini, G., Frasca, F., Conte, E., Murabito, A., Sacco, A., Genua, M., Vigneri, R., & Belfiore, A. (2006) · Endocrinology · doi:10.1210/en.2005-1610 · Cited by 106
High Prevalence of Manifestations of Gastric Autoimmunity in Parietal Cell Antibody- Positive Type 1 (Insulin-Dependent) Diabetic Patients1
Block, C. E. M. D., Leeuw, I. H. D., & Gaal, L. F. V. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6095 · Cited by 104
Hypogonadism and diabetes
Betancourt-Albrecht, M., & Cunningham, G. R. (2003) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901031 · Cited by 102
Type 2 Diabetes Mellitus: The Impact on Colorectal Adenoma Risk in Women
Elwing, J. E., Gao, F., Davidson, N. O., & Early, D. S. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00651.x · Cited by 96
Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System
Ramos-Nino, M. E., MacLean, C. D., & Littenberg, B. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-17 · Cited by 92
Insulin Increases Lipogenic Enzyme Activity in Human Adipocytes in Primary Culture
Moustaïd, N., Jones, B. H., & Taylor, J. W. (1996) · Journal of Nutrition · doi:10.1093/jn/126.4.865 · Cited by 90
Seroprevalence of Hepatitis B and C in Type 2 Diabetic Patients
Chen, H.-F., Li, C., Chen, P., See, T.-T., & Lee, H. (2006) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(09)70195-9 · Cited by 87
Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy.
Noy, A., & Bilezikian, J. P. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.5.7962312 · Cited by 87
Diabetes as a risk factor for death following endometrial cancer
Folsom, A. R., Anderson, K. E., Sweeney, C., & Jacobs, D. R. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.06.027 · Cited by 86
Hyperglycemia regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231
Turturro, F., Friday, E., & Welbourne, T. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-96 · Cited by 86
Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?
Goodwin, P. J., Ennis, M., Fantus, I. G., Pritchard, K. I., Trudeau, M., Koo, J., & Hood, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.048 · Cited by 86
Targeting the adiponectin leptin ratio for postmenopausal breast cancer prevention
Cleary, M. P. (2009) · Frontiers in Bioscience-Scholar · doi:10.2741/s30 · Cited by 85
Inhaled insulin for diabetes mellitus
Mandal, T. K. (2005) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp040249 · Cited by 82
History of treated hypertension and diabetes mellitus and risk of renal cell cancer
Zucchetto, A., Maso, L. D., Tavani, A., Montella, M., Ramazzotti, V., Talamini, R., Canzonieri, V., Garbeglio, A., Negri, E., Franceschi, S., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl438 · Cited by 80
Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma
de Aguirre, Boya, P., Bellet, D. H., Faivre, S. J., Troalen, F., Bénard, J., Saulnier, P., Hopkins-Donaldson, S., Zangemeister‐Wittke, U., Kroemer, G., et al. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000045781.46314.e2 · Cited by 78
Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and β-arrestin1
Vasilcanu, R., Vasilcanu, D., Rosengren, L., Natalishvili, N., Sehat, B., Yin, S., Girnita, A., Axelson, M., Girnita, L., & Larsson, O. (2007) · Oncogene · doi:10.1038/sj.onc.1210797 · Cited by 78
Proliferative effects of insulin analogues on mammary epithelial cells
Mayer, D., Shukla, A. K., & Enzmann, H. G. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801900645 · Cited by 78
Chronic activation of AMP-activated kinase as a strategy for slowing aging
McCarty, M. F. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.01.043 · Cited by 77
Putative Pancreatic Cancer-Associated Diabetogenic Factor: 2030 MW Peptide
Basso, D., Valerio, A., Seraglia, R., Mazza, S., Piva, M. G., Greco, E., Fogar, P., Gallo, N., Pedrazzoli, S., Tiengo, A., et al. (2002) · Pancreas · doi:10.1097/00006676-200201000-00002 · Cited by 77
Controlling Hyperglycemia as an Adjunct to Cancer Therapy
Krone, C. A., & Ely, J. T. A. (2005) · Integrative Cancer Therapies · doi:10.1177/1534735404274167 · Cited by 76
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors
Mulvihill, M. J., Ji, Q., Coate, H. R., Cooke, A. R., Dong, H., Feng, L., Foreman, K. W., Rosenfeld-Franklin, M., Honda, A., Mak, G., et al. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.061 · Cited by 76
Insulin increases fatty acid synthase gene transcription in human adipocytes
Claycombe, K., Jones, B. H., Standridge, M. K., Guo, Y., Chun, J. T., Taylor, J. W., & Moustaïd‐Moussa, N. (1998) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1998.274.5.r1253 · Cited by 76
Obesity and Mortality from Cancer
Adami, H., & Trichopoulos, D. (2003) · New England Journal of Medicine · doi:10.1056/nejmp030029 · Cited by 75
Insulin and its analogs: actions via insulin and IGF receptors
Vigneri, R., Squatrito, S., & Sciacca, L. (2010) · Acta Diabetologica · doi:10.1007/s00592-010-0215-3 · Cited by 71
The insulin-pancreatic acinar axis
Williams, J. A., & Goldfine, I. D. (1985) · Diabetes · doi:10.2337/diabetes.34.10.980 · Cited by 69
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth
Gable, K., Maddux, B. A., Peñaranda, C., Zavodovskaya, M., Campbell, M. J., Lobo, M., Robinson, L., Schow, S. R., Kerner, J. A., Goldfine, I. D., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0397 · Cited by 68
Obesity and cancer
Vigneri, P. G., Frasca, F., Sciacca, L., Frittitta, L., & Vigneri, R. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.013 · Cited by 61
Role of the time factor in signaling specificity: Application to mitogenic and metabolic signaling by the insulin and insulin-like growth factor-I receptor tyrosine kinases
MEYTS, P. D., Christoffersen, C. T., Ursø, B., Wallach, B. J., Grønskov, K., Yakushiji, F., & Shymko, R. M. (1995) · Metabolism · doi:10.1016/0026-0495(95)90214-7 · Cited by 59
Human fatty acid synthase mRNA: tissue distribution, genetic mapping, and kinetics of decay after glucose deprivation
Semenkovich, C. F., Coleman, T., & Fiedorek, F. T. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39738-8 · Cited by 57
Aromatase regulation and breast cancer
Reed, M. J., & Purohit, A. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01276.x · Cited by 53
Diabetes mellitus and kidney cancer risk: The results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study)
Washio, M., Mori, M., Khan, M., Sakauchi, F., Watanabe, Y., Ozasa, K., Hayashi, K., Miki, T., Nakao, M., Mikami, K., et al. (2007) · International Journal of Urology · doi:10.1111/j.1442-2042.2007.01744.x · Cited by 52
Temsirolimus, an mTOR Inhibitor for Treatment of Patients With Advanced Renal Cell Carcinoma
Malizzia, L., & Hsu, A. D. (2008) · Clinical journal of oncology nursing · doi:10.1188/08.cjon.639-646 · Cited by 51
Recombinant Human Insulin-Like Growth Factor-I Treatment Inhibits Gluconeogenesis in a Transgenic Mouse Model of Type 2 Diabetes Mellitus
Pennisi, P., Gavrilova, O., Setser-Portas, J., Jou, W., Santopietro, S., Clemmons, D., Yakar, S., & LeRoith, D. (2006) · Endocrinology · doi:10.1210/en.2005-1556 · Cited by 51
Effect of High-Carbohydrate Feeding on Triglyceride and Saturated Fatty Acid Synthesis
Hudgins, L. C. (2000) · Proceedings of the Society for Experimental Biology and Medicine · doi:10.1046/j.1525-1373.2000.22521.x · Cited by 49
Frequency of cancer among insulin-treated diabetic patients in Denmark
Green, A., & Jensen, O. M. (1985) · Diabetologia · doi:10.1007/bf00273858 · Cited by 45
Is exercise an effective treatment for NASH? Knowns and unknowns
Caldwell, S., & Lazo, M. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31828-9 · Cited by 42
Role of c-Abl in Directing Metabolic versus Mitogenic Effects in Insulin Receptor Signaling
Frasca, F., Pandini, G., Malaguarnera, R., Mandarino, A., Messina, R. L., Sciacca, L., Belfiore, A., & Vigneri, R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705008200 · Cited by 35
Diabetes Mellitus as a Risk Factor for Cancer: Stress or Viral Etiology?
Cebioglu, M., Schild, H. H., & Golubnitschaja, O. (2008) · Infectious Disorders - Drug Targets · doi:10.2174/187152608784746501 · Cited by 31
The PPARγ agonist pioglitazone prevents the hyperglycemia caused by phosphoinositide-3-kinase pathway inhibition by PX-866 without affecting antitumor activity
Ihle, N., Lemos, R., Schwartz, D., Oh, J., Halter, R., Wipf, P., Kirkpatrick, L., & Powis, G. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0714 · Cited by 30
Inhaled insulin—what went wrong
Mitri, J., & Pittas, A. G. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1007 · Cited by 28
High Titer of Autoantibodies to GAD Identifies a Specific Phenotype of Adult-Onset Autoimmune Diabetes
Buzzetti, R., Petrone, A., Capizzi, M., Bosi, E., & for the Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study Group (2007) · Diabetes Care · doi:10.2337/dc07-1397 · Cited by 28
Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy
Noy, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.5.1223 · Cited by 28
Chapter 4 c‐Abl and Insulin Receptor Signalling
Genua, M., Pandini, G., Cassarino, M. F., Messina, R. L., & Frasca, F. (2009) · Vitamins and hormones · doi:10.1016/s0083-6729(08)00604-3 · Cited by 27
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors
Zimmermann, K., Wittman, M. D., Saulnier, M. G., Velaparthi, U., Langley, D. R., Sang, X., Frennesson, D. B., Carboni, J. M., Li, A., Greer, A. L., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.05.104 · Cited by 25
Glucose tolerance status and 20 year cancer incidence.
Dankner, R. S., Chetrit, A., & Segal, P. (2007) · PubMed · Cited by 24
Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention
Margot, P. C. (2009) · Frontiers in Bioscience-Elite · doi:10.2741/e30 · Cited by 14
Effect of High‐Carbohydrate Feeding on Triglyceride and Saturated Fatty Acid Synthesis
Hudgins, L. C. (2000) · Proceedings of The Society for Experimental Biology and Medicine · doi:10.1111/j.1525-1373.2000.22521.x · Cited by 11

Flagged first, then by citations

Research works printed but not linked: 1

Lindblad P Adami HO 2002 Kidney cancer. In Textbook of Cancer Epidemiology, pp 467–485 Eds HunterDAdamiHOTrichopoulosD. New York: Oxford University Press.

Sorted by citations

Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Diabetes and Cancer
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Economic Costs of Diabetes in the U.S. in 2012
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc12-2625 · Cited by 2,227
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,082
Molecular mechanisms of cancer development in obesity
Khandekar, M. J., Cohen, P., & Spiegelman, B. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3174 · Cited by 921

See all 1,009

Authors: Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R.
Affiliations: Section of General Pathology 1
University of Catania (IT)
Corresponding author: Vigneri, Paolo
ORCID: Vigneri, Paolo
Frasca, Francesco
Sciacca, Laura
Pandini, Giuseppe
Vigneri, Riccardo
Venue: Endocrine Related Cancer
Publisher: Bioscientifica
Published: 2009-12-01
Volume: 16
Issue: 4
Pages: 1103-1123
ISSN: 1351-0088 (ISSN-L)
1479-6821
DOI: 10.1677/erc-09-0087
OpenAlex: W2163691729
Cited by: 1,009
References: 183
Citations by year: 2026: 20 · 2025: 43 · 2024: 54 · 2023: 49 · 2022: 49 · 2021: 46 · 2020: 50 · 2019: 57 · 2018: 60 · 2017: 75 · 2016: 59 · 2015: 68 · 2014: 85 · 2013: 97 · 2012: 80
FWCI: 5.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Endocrine Related Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: Associazione Italiana per la Ricerca sul Cancro
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords: diabetes mellitus, cancer risk, hyperinsulinemia, insulin-like growth factor I, insulin receptor, metformin, antidiabetic drugs, glucocorticoids, androgen receptor antagonists, obesity, hyperglycemia, oxidative stress, pancreatic cancer, liver cancer, breast cancer, colorectal cancer, cancer mortality, confounding factors
MeSH terms: Humans, Neoplasms, Risk Factors, Survival Rate, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Diabetes and cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks